Measuring Biomarkers of Oxidative Stress in ME/CFS Patients.
Walker, Max · Methods in molecular biology (Clifton, N.J.) · 2025 · DOI
Quick Summary
This study looked at whether certain molecules in the blood and immune cells could show signs of oxidative stress (cellular damage from harmful molecules called free radicals) in ME/CFS patients. The researchers tested two different markers before and after exercise: one test successfully measured protein damage, while another test designed to measure DNA damage was not sensitive enough to detect changes in this patient group.
Why It Matters
Identifying reliable biomarkers for oxidative stress could help clinicians objectively measure disease severity and monitor treatment response in ME/CFS patients. This study provides practical guidance on which measurement methods work and which need improvement, advancing the toolkit for understanding the biochemical basis of ME/CFS and tracking disease progression.
Observed Findings
Protein carbonyl modifications in immune cell proteins were successfully detected and measured using the 2,4-dinitrophenylhydrazine ELISA assay
Protein carbonyl modifications in plasma were detectable before and during exercise protocols in ME/CFS patients
The commercial 8-OHdG DNA modification assay did not have sufficient sensitivity to measure changes in this patient population
The choice of detection technology significantly affects the ability to measure oxidative stress biomarkers in ME/CFS
Inferred Conclusions
Protein carbonyl modifications show promise as a measurable biomarker for oxidative stress in ME/CFS patients
The 8-OHdG DNA modification assay requires either technological improvements or alternative methodologies to be useful in ME/CFS research
Careful selection and validation of measurement techniques is critical when assessing oxidative stress in this population
Remaining Questions
Do protein carbonyl modifications correlate with symptom severity or disease progression over time in ME/CFS patients?
What alternative methods or technologies could successfully measure DNA oxidative modifications (8-OHdG) in ME/CFS patients?
How do oxidative stress biomarker levels in ME/CFS patients compare to healthy controls and other fatiguing illnesses?
What This Study Does Not Prove
This study does not prove that oxidative stress causes ME/CFS or that reducing oxidative stress will improve symptoms. It also does not establish that the protein carbonyl marker works equally well across all ME/CFS patient populations or stages of disease, as only moderate-functioning patients were tested.
Do oxidative stress markers change differently in severe versus mild ME/CFS populations, and would findings differ if more severely affected patients were studied?